english.prescrire.org > Spotlight > Archives : 2022 > Dapivirine vaginal ring in the prevention of HIV

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

Dapivirine vaginal ring in the prevention of HIV

 Marketing Authorisations  Fragile data from a single clinical trial suggest that the dapivirine vaginal ring has at best partial efficacy in the prevention of HIV infection, with a considerable margin of uncertainty.
Full article (4 pages) available for download by subscribers.

  • When considering drug-based prophylaxis to prevent HIV infection, a vaginal device left in place for 4 weeks that releases an antiretroviral drug could be of value to some women, especially when pre-exposure prophylaxis (PrEP) with oral emtricitabine + tenofovir is not a suitable option. But the efficacy of the intravaginally released drug would have to be established, which is not the case for the dapivirine vaginal ring as of 2022.
  • Based on the data available, its evaluation should be continued.

©Prescrire 1 December 2022

Source: "Dapivirine vaginal ring in the prevention of HIV" Prescrire International 2022; 31 (243): 285-288. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

Share on  Facebook Share on  Twitter

Read more:

All the subjects in
Prescrire's Spotlight
Free >